| 1 |
NCT03500081 |
Recruiting
New |
Solid Tumor Imaging MR‐Linac (STIM Study) |
|
|
Observational |
|
- Medical College of Wisconsin
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Determine the optimal set of scan parameters (e.g., field of view).
|
240 |
All |
18 Years and older (Adult, Senior) |
NCT03500081 |
PRO 30440 |
|
October 2, 2017 |
May 10, 2019 |
July 1, 2021 |
April 17, 2018 |
April 17, 2018 |
|
- Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 2 |
NCT03488875 |
Recruiting
New |
Impact of Mindfulness Training on Stress-related Health Outcomes in Law Enforcement |
- Stress, Psychological
- Sleep
- Inflammation
- Mental Health
|
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
- U.S. Department of Justice
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in perceived occupational stress
- Change in diurnal cortisol slope
- Change in cortisol awakening response
- (and 3 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03488875 |
2017-1529
2017-R2-CX-0033 |
|
March 6, 2018 |
December 31, 2020 |
December 31, 2020 |
April 5, 2018 |
April 12, 2018 |
|
- Center for Healthy Minds, University of Wisconsin-Madison
Madison, Wisconsin, United States
|
| 3 |
NCT03482726 |
Enrolling by invitation
New |
Cadence Modulation in Cyclists |
|
- Behavioral: Cycling Cadence Modulation
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Time to exhaustion T(max)
- Ventilatory threshold (VT)
- Maximal cardiac output
- (and 9 more...)
|
40 |
All |
18 Years to 89 Years (Adult, Senior) |
NCT03482726 |
2017-0131 |
|
June 26, 2017 |
June 25, 2019 |
December 31, 2020 |
March 29, 2018 |
March 29, 2018 |
|
- University of Wisconsin
Madison, Wisconsin, United States
|
| 4 |
NCT03480451 |
Recruiting
New |
Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis |
- Idiopathic Pulmonary Fibrosis
|
- Other: Multi-Disciplinary Patient Centered Rehab and Education
|
Interventional |
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Assess the change in coping skills for patients with IPF before and after a comprehensive pulmonary rehabilitation program.
- Assess the change in quality of life for patients with IPF before and after a comprehensive pulmonary rehabilitation program.
- Assess the change in depression, anxiety for patients with IPF before and after a comprehensive pulmonary rehabilitation program.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03480451 |
28280 |
IPF |
September 12, 2017 |
December 2018 |
December 2019 |
March 29, 2018 |
March 29, 2018 |
|
- Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin, United States
|
| 5 |
NCT03478462 |
Not yet recruiting
New |
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma |
- Pediatric Solid Tumor
- Pediatric Lymphoma
- Pediatric Brain Tumor
|
|
Interventional |
Phase 1 |
- Cellectar Biosciences, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with dose limiting toxicities (DLT)
- Determination of therapeutic activity of CLR 131 in children and adolescents
|
30 |
All |
2 Years to 21 Years (Child, Adult) |
NCT03478462 |
DCL-17-001 |
|
July 2018 |
September 2020 |
December 2020 |
March 27, 2018 |
March 27, 2018 |
|
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
| 6 |
NCT03461861 |
Not yet recruiting |
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development |
|
- Drug: Levetiracetam 250 mg
- Other: Placebo
|
Interventional |
Phase 2 |
- Medical College of Wisconsin
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Functional connectivity strengths of neural networks
- Rey Auditory Verbal Learning Test (AVLT)
- Logical memory test (LMT)
|
50 |
All |
55 Years to 75 Years (Adult, Senior) |
NCT03461861 |
PRO00031146
R21AG056882-01 |
|
May 15, 2018 |
March 31, 2019 |
March 31, 2019 |
March 12, 2018 |
April 12, 2018 |
|
- Froedtert & The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 7 |
NCT03459729 |
Not yet recruiting |
Antitumor B KAC-α PK Study |
- Squamous Cell Carcinoma of the Oral Cavity
|
- Dietary Supplement: Antitumor B KAC-α
|
Interventional |
Early Phase 1 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Antitumor B KAC-α in blood samples.
- Antitumor B KAC-α in saliva.
- Antitumor B KAC-α accumulation in tumor tissue specimen.
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT03459729 |
IIT-WONG-ATB |
|
April 1, 2018 |
May 1, 2019 |
May 1, 2020 |
March 9, 2018 |
March 9, 2018 |
|
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 8 |
NCT03455218 |
Not yet recruiting |
Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation |
- Inflammation
- Platelet Dysfunction
|
- Drug: Nitric Oxide
- Drug: Placebo
- Device: INOmax
|
Interventional |
Phase 2
Phase 3 |
- Medical College of Wisconsin
- Mallinckrodt
- Clinical & Translational Science Institute of Southeast Wisconsin
- Blood Center of Wisconsin
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Platelet Count
- 30 day mortality
- Hospital length of stay
- (and 15 more...)
|
40 |
All |
up to 1 Year (Child) |
NCT03455218 |
1111115-1NO in CPB 001 |
|
April 25, 2018 |
March 30, 2019 |
June 30, 2019 |
March 6, 2018 |
April 17, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
| 9 |
NCT03445169 |
Not yet recruiting |
A Food Effect Study in Healthy Volunteers With PT2977 Tablets |
|
|
Interventional |
Phase 1 |
- Peloton Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma Concentrations of PT2977 assessed in both the fasting and non-fasting conditions and compared
|
16 |
All |
18 Years to 45 Years (Adult) |
NCT03445169 |
PT2977-103 |
|
March 2018 |
May 2018 |
September 2018 |
February 26, 2018 |
February 27, 2018 |
|
- Spaulding Clinical
West Bend, Wisconsin, United States
|
| 10 |
NCT03443180 |
Enrolling by invitation |
Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet |
|
- Other: Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
|
Interventional |
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in the plasma-induced transcriptional assay
- Stool microbial composition
- Plasma microbial antigen detection
- Leukocyte analyses
|
50 |
All |
5 Years to 17 Years (Child) |
NCT03443180 |
1138159 |
|
January 1, 2018 |
December 31, 2020 |
December 31, 2020 |
February 23, 2018 |
February 23, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 11 |
NCT03441048 |
Not yet recruiting |
Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
- Drug: Lintuzumab AC 225
- Drug: Cladribine
- Drug: Cytarabine
- (and 2 more...)
|
Interventional |
Phase 1 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-Tolerated Dose of Lintuzumab-AC225
- Toxicities of the Combination
- Response Rates
- (and 2 more...)
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT03441048 |
ABEDIN-IIT |
|
April 1, 2018 |
April 1, 2019 |
April 1, 2020 |
February 21, 2018 |
February 21, 2018 |
|
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 12 |
NCT03434652 |
Recruiting |
Auricular Neurostimulation for Cyclic Vomiting Syndrome |
- Cyclic Vomiting Syndrome
- Abdominal Migraine
|
- Device: Percutaneous neurostimulation
|
Interventional |
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Nausea and vomiting
- Pain
- Anxiety
- (and 4 more...)
|
50 |
All |
10 Years to 65 Years (Child, Adult) |
NCT03434652 |
1102505-4 |
|
January 31, 2018 |
June 30, 2019 |
December 31, 2019 |
February 15, 2018 |
February 16, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
| 13 |
NCT03423862 |
Recruiting |
Development of Predictive Biomarkers |
|
- Other: Mixed Meal Tolerance Test
|
Observational |
|
- Medical College of Wisconsin
- Juvenile Diabetes Research Foundation
- Benaroya Research Institute
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Predicting the honeymoon period
- Establishing the relationship between baseline inflammation and other measures
|
100 |
All |
6 Years to 17 Years (Child) |
NCT03423862 |
1048169 |
|
October 1, 2017 |
September 30, 2020 |
September 30, 2020 |
February 6, 2018 |
February 7, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 14 |
NCT03423589 |
Not yet recruiting |
Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics |
- Type1diabetes
- Type1 Diabetes Mellitus
|
- Dietary Supplement: VSL#3
|
Interventional |
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Alterations in Plasma-Induced Transcriptional Analysis
- Intestinal Microbiota
|
30 |
All |
5 Years to 17 Years (Child) |
NCT03423589 |
1171017 |
|
May 1, 2018 |
December 31, 2018 |
December 31, 2018 |
February 6, 2018 |
April 17, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 15 |
NCT03417076 |
Not yet recruiting |
Absolute Bioavailability Study With Bexagliflozin |
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- absolute bioavailability (Fp.o.) of bexagliflozin tablets
- adverse events
|
8 |
Male |
18 Years to 55 Years (Adult) |
NCT03417076 |
THR-1442-C-446 |
|
April 1, 2018 |
May 16, 2018 |
May 16, 2018 |
January 31, 2018 |
March 1, 2018 |
|
- Clinical Research Site
Madison, Wisconsin, United States
|
| 16 |
NCT03412084 |
Recruiting |
A "Stand Up and Move More" Intervention for Older Adults |
|
- Behavioral: Stand up and move more
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction in Sedentary behavior (i.e., total sitting time per day)
- Short physical performance battery
|
80 |
All |
56 Years and older (Adult, Senior) |
NCT03412084 |
2013-1155
R21AG054916 |
|
March 14, 2018 |
August 2019 |
August 2019 |
January 26, 2018 |
March 21, 2018 |
|
- Kelli Koltyn
Madison, Wisconsin, United States
|
| 17 |
NCT03406923 |
Not yet recruiting |
Self-efficacy, Beliefs and Adherence- Pilot and Feasibility Trial of a Pharmacist-led Intervention |
|
- Other: Health literacy-psychosocial support
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
- Merck Sharp & Dohme Corp.
- William S. Middleton Memorial Veterans Hospital
|
Other / Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Health Services Research
|
- Change in diabetes medication adherence
- Change in diabetes control
- Self-efficacy for medication use
- (and 4 more...)
|
50 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03406923 |
2017-0951 |
|
February 1, 2018 |
December 31, 2020 |
December 31, 2020 |
January 23, 2018 |
January 23, 2018 |
|
- William S. Middleton Memorial Veterans Hospital
Madison, Wisconsin, United States
|
| 18 |
NCT03404804 |
Recruiting |
Oral Challenge in the Pediatric ED |
- Penicillin Allergy
- Pediatric Emergency Medicine
|
|
Interventional |
Phase 4 |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Oral amoxicillin challenge
- Oral amoxicillin challenge follow-up
- Cost analysis
|
100 |
All |
3 Years to 16 Years (Child) |
NCT03404804 |
1069530-3 |
OPEN |
December 4, 2017 |
December 4, 2018 |
December 4, 2018 |
January 19, 2018 |
January 19, 2018 |
|
- David Vyles
Milwaukee, Wisconsin, United States
|
| 19 |
NCT03393741 |
Recruiting |
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
- Breast Cancer
- Breast Neoplasms
|
- Drug: Taxane
- Drug: Vinorelbine
- Drug: Ixabepilone
- (and 2 more...)
|
Observational |
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Feasibility of measuring biomarkers in advanced breast tumors at 20 +/- 2 hours after chemotherapy
- Measure intratumoral drug levels at 20 +/- 2 hours after chemotherapy
- Measure serum drug levels at 20 +/- 2 hours after chemotherapy
- (and 7 more...)
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT03393741 |
UW16151
P30CA014520
NCI-2017-01614
2017-0668 |
|
January 29, 2018 |
February 28, 2019 |
February 28, 2019 |
January 8, 2018 |
March 12, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 20 |
NCT03387735 |
Recruiting |
Multiple Chronic Conditions for Older Adults |
|
- Other: Treatment as usual (TAU) + Internet
- Behavioral: TAU + C-CHESS
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
- University of Wisconsin Hospital and Clinics (UW Health)
- Medical University of South Carolina
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Health outcomes
- Healthcare use
- Chronic condition outcome: Hypertension
- (and 3 more...)
|
330 |
All |
65 Years and older (Adult, Senior) |
NCT03387735 |
2017-0849 |
|
January 1, 2018 |
June 2021 |
June 2021 |
January 2, 2018 |
February 20, 2018 |
|
- UW Health Clinics
Madison, Wisconsin, United States
|
| 21 |
NCT03387514 |
Recruiting |
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies |
|
- Drug: PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
|
Interventional |
Phase 2 |
- University of Wisconsin, Madison
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- RECIST 1.1 Based Criteria
- HIstopathological Endpoints
- Measure therapy response of patient specific uVESSEL (a micro scale organotypic co-culture model)
- Evaluate the predictive power and validate the uVESSEL model
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT03387514 |
2017-1343
P30CA014520 |
UW17104 |
January 15, 2018 |
January 15, 2021 |
January 15, 2022 |
January 2, 2018 |
January 24, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 22 |
NCT03381339 |
Recruiting |
Powertoothbrushing for Treating Gingivitis |
- Gingivitis, Treatment, Oral Hygiene
|
- Device: Oscillating rotating power toothbrush
|
Interventional |
Not Applicable |
- Marquette University
- Sunstar, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Reduction in Gingivitis
- Single use reduction in overnight plaque
- Reduction in overnight plaque formation
|
70 |
All |
18 Years to 65 Years (Adult) |
NCT03381339 |
MarquetteU |
|
December 5, 2017 |
June 25, 2018 |
June 25, 2018 |
December 22, 2017 |
December 22, 2017 |
|
- Marquette University School of Dentistry
Milwaukee, Wisconsin, United States
|
| 23 |
NCT03378505 |
Active, not recruiting |
Impact of Mobile App on Purpose and Well-Being Among College Students |
|
- Behavioral: Mobile App
- Behavioral: Reflection
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change in Health Behaviors
- Change in Resiliency
- Change in Self-Regulation
- (and 3 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03378505 |
2017-1371 |
PWB |
January 24, 2018 |
May 2018 |
January 2019 |
December 19, 2017 |
March 8, 2018 |
|
- School of Human Ecology
Madison, Wisconsin, United States
|
| 24 |
NCT03375892 |
Recruiting |
A Phase II Study of the Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure |
- Breast Cancer
- Ductal Carcinoma in Situ
- Invasive Breast Cancer
|
- Other: Deep Inspiration Breath Hold and Free-breathing
|
Interventional |
Phase 2 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of a radiation technique for patients treated for left-sided breast cancer that minimizes exposure to the heart, as measured by the mean heart dose.
- Changes in EKG readings prior to, during or after radiation therapy.
- Changes in echocardiogram parameters prior to, during or after radiation therapy.
- Change in mitochondrial energy production, as measured in leukocytes (peripheral blood mononuclear cells) from patients prior to and after undergoing radiation therapy.
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT03375892 |
IIT-Bergom |
|
March 3, 2018 |
June 30, 2019 |
June 30, 2020 |
December 18, 2017 |
April 12, 2018 |
|
- Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 25 |
NCT03375619 |
Recruiting |
Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells |
- CLL/SLL
- Lymphomas Non-Hodgkin's B-Cell
|
- Other: Long-Term Follow-Up of Patients who Received CAR-20/19-T cells
|
Observational |
|
- Medical College of Wisconsin
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Proportion of patients with listed categories: new malignancies, new incidence or exacerbation of a prior rheumatologic or other autoimmune disorder, new incidence of a hematologic disorder.
- Proportion of patients who relapse or progress among patients who had not relapsed or progressed at study entry from CAR-20/19 T cell treatment; Incidence of death.
- Absolute B- and T-lymphocyte counts.
- (and 2 more...)
|
24 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03375619 |
PRO30317 |
|
December 1, 2017 |
August 1, 2020 |
August 1, 2040 |
December 18, 2017 |
March 23, 2018 |
|
- Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 26 |
NCT03369054 |
Recruiting |
Psychotherapy Trial With Transgender Clients |
- Transgender Persons, M01.777.500
|
- Behavioral: Minority Stress Treatment
- Behavioral: Treatment As usual
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Measuring Weekly Change in the Outcome Questionnaire 45; Lambert et al., 2013
- Measuring 3 month and 9 month Change in the Outcome Questionnaire 45; Lambert et al., 2013
- Measuring 3 month and 9 month Change in the World Health Organization WHOQOL-BREF Quality of Life Assessment (WHOQOL-BREF); Power, 1998
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT03369054 |
2017-0816 |
|
December 2017 |
August 2018 |
August 2018 |
December 11, 2017 |
December 11, 2017 |
|
- University of Wisconsin Madison
Madison, Wisconsin, United States
|
| 27 |
NCT03363659 |
Recruiting |
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme |
- Glioblastoma
- Glioblastoma Multiforme
|
- Drug: Disulfiram
- Dietary Supplement: Copper gluconate
- Drug: Temozolomide
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate
- Six months progression-free survival
- Toxicity
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03363659 |
17.56 |
|
May 21, 2018 |
January 21, 2026 |
January 21, 2027 |
December 6, 2017 |
April 4, 2018 |
|
- Aurora Health Care, Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States
|
| 28 |
NCT03358563 |
Recruiting |
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer |
|
- Drug: Docetaxel
- Drug: Degarelix
- Drug: Bicalutamide
|
Interventional |
Early Phase 1 |
- University of Wisconsin, Madison
- United States Department of Defense
- National Cancer Institute (NCI)
|
Other / U.S. Fed / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in pCR rates
- Change in PSA
- PSA Recurrence
- Safety and tolerability of combination ADT and docetaxel measured by CTCAE v.4.0
|
30 |
Male |
18 Years and older (Adult, Senior) |
NCT03358563 |
UW17009
P30CA014520
2017-0606 |
|
January 5, 2018 |
January 2019 |
January 2020 |
November 30, 2017 |
April 17, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 29 |
NCT03356470 |
Enrolling by invitation |
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma |
|
|
Observational |
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation of baseline of response and antitumor response
- Correlation of in vivo clonally amplified T cells to FDG PET uptake in melanoma tumors
- To correlate histologic and molecular markers of antitumor response to FLT PET uptake in melanoma tumors following treatment with anti-PD-1
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT03356470 |
UW16032
2017-0046
P30CA014520 |
|
November 2, 2017 |
December 2018 |
December 2018 |
November 29, 2017 |
December 12, 2017 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 30 |
NCT03352908 |
Recruiting |
Yale Swallow Protocol in Extubated Patients |
|
|
Observational |
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Determine the sensitivity of the Yale Swallow Protocol (YSP) through aspiration identification in recently extubated patients.
|
188 |
All |
18 Years and older (Adult, Senior) |
NCT03352908 |
2016-1149 |
|
October 25, 2017 |
August 13, 2018 |
August 13, 2018 |
November 24, 2017 |
November 24, 2017 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
| 31 |
NCT03349125 |
Active, not recruiting |
Study: C-Collar and Dysphagia |
|
- Behavioral: Collar On
- Behavioral: Collar Off
|
Observational |
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- To identify aspiration between study conditions (with and without a collar).
|
23 |
All |
60 Years and older (Adult, Senior) |
NCT03349125 |
2017-0222 |
|
September 17, 2013 |
May 17, 2017 |
April 30, 2018 |
November 21, 2017 |
January 4, 2018 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
| 32 |
NCT03349112 |
Recruiting |
Study: Manometry With & Without Lidocaine |
|
- Behavioral: 4% Lidocaine Spray
- Behavioral: 2% Viscous Lidocaine
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- A quantifiable difference of perceived comfort reduction during HRPM with or without lidocaine as assessed through analysis of a visual analog scale.
|
36 |
All |
18 Years to 65 Years (Adult) |
NCT03349112 |
2015-0485 |
|
December 22, 2015 |
December 2020 |
December 2020 |
November 21, 2017 |
November 21, 2017 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
| 33 |
NCT03349086 |
Recruiting |
Effects of Vocal Exercises for Spasmodic Dysphonia |
- Adductor Spasmodic Dysphonia
|
- Behavioral: Voice Exercise
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- A quantifiable difference between the effects of voice exercise vs. voice rest post Adductor Spasmodic Dysphonia botox treatment through analysis of the Voice Handicap Index Questionnaire.
|
40 |
Female |
21 Years to 70 Years (Adult, Senior) |
NCT03349086 |
2013‐1746 |
|
July 28, 2014 |
April 30, 2018 |
April 30, 2018 |
November 21, 2017 |
November 21, 2017 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
| 34 |
NCT03342378 |
Not yet recruiting |
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients |
- Squamous Cell Carcinoma
- Oropharynx Cancer
|
- Radiation: Intensity modulated radiotherapy (IMRT)
- Drug: Chemotherapy
- Diagnostic Test: PET-MRI
|
Observational |
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
- National Institute of Dental and Craniofacial Research (NIDCR)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To determine if the primary tumor response in patients with IR HPV-positive
- To define the difference of the primary tumor response in patients with LR HPV-positive OPSCC and HPV-negative OPSCC following 2 weeks of CRT.
|
58 |
All |
18 Years and older (Adult, Senior) |
NCT03342378 |
UW17078
P30CA014520
2017-1010
P50DE026787 |
|
April 2018 |
October 2020 |
October 2022 |
November 17, 2017 |
February 12, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 35 |
NCT03342157 |
Recruiting |
Docusate/Senna for the Treatment of Diabetic Gastroparesis |
|
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD)
- Frequency of use of breakthrough medication
- Frequency of bowel movements
|
60 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03342157 |
17.120 |
|
April 2, 2018 |
January 25, 2019 |
January 25, 2019 |
November 14, 2017 |
April 4, 2018 |
|
- Aurora Health Care
Milwaukee, Wisconsin, United States
|
| 36 |
NCT03336125 |
Enrolling by invitation |
Key Nutrients and Mental Health |
|
- Dietary Supplement: Vitamin D
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
- University of Bergen
- Wisconsin Department of Health and Family Services
- Haukeland University Hospital
- National Institute of Nutrition and Seafood Research, Norway
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Change in vitamin D level in blood from pre-test (baseline) to post-test (after 4 months)
- Change in serotonin from pre-test (baseline) to post-test (after 4 months)
- Change in total cholesterol from pre-test (baseline) to post-test (after 4 months)
- (and 15 more...)
|
100 |
Male |
18 Years and older (Adult, Senior) |
NCT03336125 |
983 974 724 |
|
November 2017 |
May 2018 |
May 2018 |
November 8, 2017 |
November 8, 2017 |
|
- Sand Ridge Secure Treatment Center
Mauston, Wisconsin, United States
|
| 37 |
NCT03328520 |
Enrolling by invitation |
WILD 5 Wellness, A 30-Day Intervention |
- Anxiety
- Depression
- Cognitive Functioning
- Wellness
|
- Behavioral: WILD 5 Wellness Intervention
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in Patient Health Questionnaire-9 (PHQ-9)
- Change in Generalized Anxiety Disorder-7 (GAD-7)
- Change in the HERO Wellness Scale
- (and 3 more...)
|
33 |
All |
17 Years and older (Child, Adult, Senior) |
NCT03328520 |
374 |
|
October 24, 2017 |
November 28, 2017 |
November 28, 2017 |
November 1, 2017 |
November 1, 2017 |
|
- Beloit College
Beloit, Wisconsin, United States
|
| 38 |
NCT03321916 |
Recruiting |
MacTel Laser Study |
|
- Device: 577-nm PASCAL laser
|
Interventional |
Not Applicable |
- The Lowy Medical Research Institute Limited
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Change from baseline cone density as measured by confocal adaptive optics (AOSLO)
- Change in size of ellipsoid zone break area as measured by spectral domain optical coherence tomography (SD-OCT)
- Development or extension post therapy of areas of deficiency in cones as measured by AOSLO
|
12 |
All |
21 Years to 79 Years (Adult, Senior) |
NCT03321916 |
MacTelLaser1 |
|
October 2017 |
December 2019 |
December 2019 |
October 26, 2017 |
October 26, 2017 |
|
- Medical College of Wisconsin & Froedtert Hospital
Milwaukee, Wisconsin, United States
|
| 39 |
NCT03311126 |
Recruiting |
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma |
- Mantle Cell Lymphoma
- Non-hodgkin Lymphoma
- Non Hodgkin Lymphoma
|
- Drug: Bendamustine
- Drug: Obinutuzumab
|
Interventional |
Phase 2 |
- University of Wisconsin, Madison
- Genentech, Inc.
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) at 2 years
- Minimal Residual Disease (MRD) status
- Estimate the concordance rate between peripheral blood (PB) and bone marrow aspirates (BMA) in predicting MRD status.
- (and 3 more...)
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT03311126 |
UW16086
P30CA014520
2017-0609
NCI-2017-01729 |
|
October 19, 2017 |
May 15, 2024 |
May 15, 2026 |
October 16, 2017 |
April 25, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 40 |
NCT03308669 |
Completed |
A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate |
|
- Drug: Lasmiditan
- Drug: Placebo
- Drug: Topiramate
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
- Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan, Topiramate, and Lasmiditan with Topiramate
- Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of Lasmiditan, Topiramate, and Lasmiditan with Topiramate
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT03308669 |
16925
H8H-MC-LAHT |
|
October 16, 2017 |
December 2, 2017 |
December 2, 2017 |
October 12, 2017 |
January 30, 2018 |
|
- Covance Madison CRU
Madison, Wisconsin, United States
|
| 41 |
NCT03305042 |
Completed |
Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death |
- Vitamin A Deficiency
- Vitamin A Toxicity
|
|
Observational |
|
- University of Wisconsin, Madison
- National Institute on Deafness and Other Communication Disorders (NIDCD)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Cross-Sectional
|
- Serum retinyl esters, nmol/L
- Liver vitamin A reserves, µmol/g
- Serum retinol, µmol/L
- Liver alpha-retinyl ester, nmol/g
|
27 |
All |
21 Years and older (Adult, Senior) |
NCT03305042 |
2015-1482 |
|
February 1, 2012 |
January 31, 2017 |
January 31, 2017 |
October 9, 2017 |
October 17, 2017 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
| 42 |
NCT03304002 |
Recruiting |
Implementation of a Web-based Decision Aid for Breast Cancer Surgery |
|
- Other: Breast Cancer Surgery Decision Aid
|
Observational |
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Reach
- Acceptability
- Barriers and Facilitators to Implementation of the Decision Aid
|
116 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03304002 |
UWCCC-2017-0588 |
|
August 1, 2017 |
August 31, 2018 |
November 1, 2018 |
October 6, 2017 |
February 22, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 43 |
NCT03302897 |
Active, not recruiting |
Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers |
|
- Biological: LEP-F1 + GLA-SE
|
Interventional |
Phase 1 |
- IDRI
- American Leprosy Missions
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of adverse events
- Immunogenicity (IgG antibody and T cell responses to LEP-F1)
|
24 |
All |
18 Years to 55 Years (Adult) |
NCT03302897 |
IDRI-LEPVPX-118 |
|
October 2, 2017 |
January 2019 |
January 2019 |
October 5, 2017 |
January 24, 2018 |
|
- Covance Clinical Research Unit
Madison, Wisconsin, United States
|
| 44 |
NCT03302156 |
Recruiting |
PSMA PET and MRI in Gynecological Cancers |
|
- Drug: PSMA-based 18F-DCFPyL PET tracer
|
Interventional |
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic accuracy
- Biodistribution of PSMA
- Radiodosimetry of PSMA
- Sensitivity and specificity of PSMA-based PET/MR
|
52 |
Female |
18 Years to 99 Years (Adult, Senior) |
NCT03302156 |
2017-0456
UW17017 |
|
August 10, 2017 |
August 1, 2019 |
August 1, 2020 |
October 4, 2017 |
March 13, 2018 |
|
- University of Wisconsin, Madison
Madison, Wisconsin, United States
|
| 45 |
NCT03300258 |
Not yet recruiting |
Robotic Pedaling Therapy for Targeted Neural Plasticity |
|
- Device: Robotic therapy
- Device: Aerobic therapy
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in Six Minute Walk Test (6MWT) Distance
- Change in Brain Activity in and near Affected Areas, through Functional MRI
- Change in Timed Up-and-Go Test (TUG)
- (and 3 more...)
|
100 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03300258 |
2016-1279 |
|
January 1, 2018 |
March 2022 |
March 2022 |
October 3, 2017 |
October 3, 2017 |
|
- University of Wisconsin, Madison
Madison, Wisconsin, United States
|
| 46 |
NCT03298724 |
Recruiting |
Teachers and Parents as Partners During Middle School |
|
- Behavioral: Teachers and Parents as Partners
|
Interventional |
Not Applicable |
- University of Wisconsin, Madison
- U.S. Department of Education
|
Other / U.S. Fed |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Direct Behavior Ratings (change over time)
|
100 |
All |
8 Years to 16 Years (Child) |
NCT03298724 |
2017-0872 |
|
September 2017 |
July 2018 |
July 2018 |
October 2, 2017 |
October 2, 2017 |
|
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
| 47 |
NCT03297125 |
Recruiting |
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI |
- Newly Diagnosed Glioblastoma
- Glioblastoma
|
- Device: NovoCure-TTF-200A
|
Interventional |
Phase 4 |
- Medical College of Wisconsin
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- In comparing the difference in the proportion of survival predicted by the two methods (standard versus advanced MRI), a McNemar test will be used.
- Using diffusion-weighted imaging (DWI), collect images at several different diffusion weightings and evaluate them by applying several different post-processing techniques.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03297125 |
PRO00000087 |
|
December 1, 2017 |
May 1, 2019 |
May 1, 2020 |
September 29, 2017 |
December 6, 2017 |
|
- Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 48 |
NCT03294603 |
Completed |
Radiolabeled Study of CC-220 in Healthy Male Subjects |
|
- Drug: CC-220
- Radiation: [14C]
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics -Total [14C]-Radioactivity (RA)
- Pharmacokinetics - Cumulative excretion of total [14C]-RA
- Pharmacokinetics - Total [14C]-RA whole blood-to-plasma
- (and 6 more...)
|
6 |
Male |
18 Years to 55 Years (Adult) |
NCT03294603 |
CC-220-CP-006
U1111-1202-3955 |
|
September 11, 2017 |
October 16, 2017 |
October 16, 2017 |
September 27, 2017 |
October 25, 2017 |
|
- Covance Clinical Research Unit
Madison, Wisconsin, United States
|
| 49 |
NCT03286972 |
Recruiting |
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning |
|
|
Observational |
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Percentage of participants able to complete the PET/MRI examination
- Changes in staging between PET/CT and PET/MRI
- Feasibility of PET/MRI in radiation treatment planning workflow
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03286972 |
UW16064
P30CA014520
2017-0162 |
|
September 12, 2017 |
October 2019 |
April 2020 |
September 19, 2017 |
December 13, 2017 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 50 |
NCT03284307 |
Recruiting |
UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study |
- Unconsciousness
- Consciousness
|
- Drug: Dexmedetomidine
- Drug: Ketamine
- Drug: Propofol
- Drug: Sevoflurane
|
Interventional |
Phase 4 |
- University of Wisconsin, Madison
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Spontaneous EEG slow wave activity
|
80 |
All |
18 Years to 40 Years (Adult) |
NCT03284307 |
2015-1399 |
UN-CONSCIOUS |
August 10, 2017 |
August 10, 2019 |
August 10, 2021 |
September 15, 2017 |
September 15, 2017 |
|
- UW Hospital and Clinics
Madison, Wisconsin, United States
|
Create an RSS feed from your search for:
Download the search results for: